• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 12.63
  • VXN 15.09
  • VXO 12.29
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





Company Profile

Bristol-Myers Squibb Company, a global biopharmaceutical company, engages in discovering, developing, and delivering medicines that help patients prevail over serious diseases. The company focuses on areas of serious unmet medical need, such as affective (psychiatric) disorders, Alzheimer?s/dementia, cardiovascular (primarily atherosclerosis/thrombosis), diabetes, hepatitis, HIV/AIDS, obesity, oncology, rheumatoid arthritis and related diseases, and solid organ transplant. Its products include PLAVIX for protection against fatal or non-fatal heart attack or stroke, and AVAPRO/AVALIDE for the treatment of hypertension and diabetic nephropathy; REYATAZ and SUSTIVA Franchise for the treatment of HIV, and BARACLUDE for the treatment of chronic hepatitis B infection; ERBITUX, SPRYCEL, and IXEMPRA for treating oncology related diseases; ABILIFY, a medicine for the treatment of mental illness; ORENCIA, a medicine for rheumatoid arthritis; and ONGLYZA for the treatment of type 2 diabetes. The company also has a pipeline with compounds in phase III clinical trials, including apixaban, belatacept, brivanib, dapagliflozin, ipilimumab, necitumumab, and XL-184. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. Bristol-Myers Squibb Company has various alliances and collaborations with sanofi-aventis; Otsuka Pharmaceutical Co., Ltd.; Eli Lilly and Company; Gilead Sciences, Inc.; AstraZeneca PLC; Pfizer Inc.; Exelixis, Inc.; ZymoGenetics, Inc.; and Alder Biopharmaceuticals, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

YES
     
()
Last Trade Date
Change % Price Change
Open 52 Week High
High 52 Week Low
Low Type
Volume Average Volume
Prev Close Stock Exchange
Bid Ask
Bid Size Ask Size
1st Yr Estimated EPS Growth 2nd Yr Estimated EPS Growth
2 Years Forward Earning Yield 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share Book Value Yield
Buy Back Yield CAPE Ratio
Cash Return Cash Flow per Share
Cash Flow Yield Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue EV / Pre Tax Income
EV / Revenue EV / Total Asset
Expected Dividend Growth Rate Free Cash Flow per Share
Free Caash Flow Ratio Free Cash Flow Yield
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio
PB Ratio PB Ratio 10 Year Growth
PB Ratio 3 Year Growth Cash Ratio 3 Year Average
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average PE Ratio 10 Year Growth
PE Ratio 10 Year High PE Ratio 10 Year Low
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg Price Change 1 Month
Price to Cash Ratio Price / EBITDA
Price to Sales Ratio Price to Sales Ratio 10 Year Growth
Price to Sales Ratio 3 Year Avg Price to Sales Ratio 5 Year Avg
Sale per Share Sales Yield
Sustainable Growth Rate Tangible Book Value per Share
Tangible Book Value per Share 3 year Avg Tangible Book Value per Share 5 year Avg
Total Asset per Share Total Yield
Working Capital per Share Working Capital per Share 3 Year Avg
Working Capital per Share 5 Year Avg Beta